新辅助化疗对上皮性卵巢癌患者血清肿瘤标志物及生存时间的影响

Effect of neoadjuvant chemotherapy on serum tumor markers and survival time in patients with epithelial ovarian cancer

目的探讨新辅助化疗(NAC)对上皮性卵巢癌患者血清肿瘤标志物及生存时间的影响。方法选取2014年3月至2015年6月运城市中心医院上皮性卵巢癌患者90例作为研究对象,按照随机数字表法分为对照组与观察组,每组45例。对照组行常规术后化疗,观察组在对照组化疗的基础上加用NAC治疗。对比两组临床疗效、血清肿瘤标志物水平及患者生存时间。结果观察组治疗有效率以及疾病控制率较对照组高,差异有统计学意义(P<0.05)。两组患者治疗后的癌坯抗原(CEA)、癌抗原(CA125)、人附睾蛋白4(HE4)比治疗前有显著下降,且观察组较对照组上述指标改善情况佳,差异有统计学意义(P<0.05)。观察组患者1年生存率、2年生存率、3年生存率均明显高于对照组,差异有统计学意义(P<0.05)。结论 NAC治疗晚期上皮性卵巢癌能够提高患者临床疗效,降低血清CEA、CA125、HE4肿瘤标志物的含量,提高患者生存率,值得临床广泛推广。

Objective To investigate the effect of neoadjuvant chemotherapy (NAC) on serum tumor markers and survival time in patients with epithelial ovarian cancer. Methods Ninety cases of epithelial ovarian cancer in the Central Hospital of Yuncheng from March 2014 to June 2015 were selected as the research subjects and were divided into control group and observation group according to the random number table method, with 45 cases in each group. The control group was treated with routine postoperative chemotherapy, and the observation group was treated with NAC on the basis of the control group. The clinical effects, the levels of serum tumor markers and the patient’s survival time were compared between the two groups. Results The effective rate of treatment and the rate of disease control were higher in the observation group than those in the control group(P<0.05). After treatment, the levels of cancer antigen (CEA), cancer antigen (CA125) and human epididymis protein 4 (HE4) were significantly lower than those before treatment, and the improvement of the above indexes in the observation group was better than that of the control group (P<0.05), the 1-year survival rate, 2-year survival rate and 3-year survival rate in the observation group were significantly higher than those in the control group(P<0.05). Conclusions NAC can improve the clinical efficacy on advanced epithelial ovarian cancer, and reduce the content of serum CEA, CA125, HE4 tumor markers and improve the survival rate of patients. It is worth popularizing in clinics.